Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis by Hasan, SS et al.
Vol.:(0123456789) 
Journal of Thrombosis and Thrombolysis 
https://doi.org/10.1007/s11239-020-02235-z
Venous thromboembolism in critically ill COVID-19 patients receiving 
prophylactic or therapeutic anticoagulation: a systematic review 
and meta-analysis
Syed Shahzad Hasan1  · Sam Radford2,3 · Chia Siang Kow4 · Syed Tabish Razi Zaidi5,6
 
© The Author(s) 2020
Abstract
Many aspects of care such as management of hypercoagulable state in COVID-19 patients, especially those admitted to 
intensive care units is challenging in the rapidly evolving pandemic of novel coronavirus disease 2019 (COVID-19). We 
seek to systematically review the available evidence regarding the anticoagulation approach to prevent venous thromboem-
bolism (VTE) among COVID-19 patients admitted to intensive care units. Electronic databases were searched for studies 
reporting venous thromboembolic events in patients admitted to the intensive care unit receiving any type of anticoagulation 
(prophylactic or therapeutic). The pooled prevalence (and 95% confidence interval [CI]) of VTE among patients receiving 
anticoagulant were calculated using the random-effects model. Subgroup pooled analyses were performed with studies 
reported prophylactic anticoagulation alone and with studies reported mixed prophylactic and therapeutic anticoagulation. 
We included twelve studies (8 Europe; 2 UK; 1 each from the US and China) in our systematic review and meta-analysis. 
All studies utilized LMWH or unfractionated heparin as their pharmacologic thromboprophylaxis, either prophylactic doses 
or therapeutic doses. Seven studies reported on the proportion of patients with the previous history of VTE (range 0–10%). 
The pooled prevalence of VTE among ICU patients receiving prophylactic or therapeutic anticoagulation across all studies 
was 31% (95% CI 20–43%). Subgroup pooled analysis limited to studies reported prophylactic anticoagulation alone and 
mixed (therapeutic and prophylactic anticoagulation) reported pooled prevalences of VTE of 38% (95% CI 10–70%) and 27% 
(95% CI 17–40%) respectively. With a high prevalence of thromboprophylaxis failure among COVID-19 patients admitted 
to intensive care units, individualised rather than protocolised VTE thromboprophylaxis would appear prudent at interim.
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Highlights
• Despite receiving anticoagulation for thromboprophy-
laxis, a high rate of venous thromboembolism was still 
observed among COVID-19 patients admitted to the 
intensive care unit.
• The failure rate of pharmacological thromboprophylaxis 
may be lower with the use of therapeutic anticoagulation 
among COVID-19 patients admitted to the intensive care 
unit.
• An individualized dosing approach of anticoagulant 
based on anti-factor Xa monitoring, thromboelastogra-
phy, or rotational thromboelastometry may be useful to 
reduce the rate of venous thromboembolism COVID-19 
patients.
Electronic supplementary material The online version of this 
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Introduction
The novel coronavirus disease 2019 (COVID-19) has 
claimed over 500,000 lives and infected well over 9 million 
people as of 27th June 2020 [1]. COVID-19 infection has 
demonstrated a range of phenotypes from asymptomatic, all 
the way to multiorgan failure and death. Among the COVID-
19 population admitted to intensive care units (ICUs) there 
has been considerable reporting of venous thromboembo-
lism (VTE). Though hypercoagulability in COVID-19 has 
been well-recognized, uncertainty still exists as to how best 
to manage clotting risk in these patients. Like many aspects 
of care in this rapidly evolving pandemic, the evidence is 
scarce with adequate quality to inform the approach to the 
hypercoagulable state in COVID-19 patients.
Since the recognition of the hypercoagulable state in 
COVID-19 patients, several interim guidance documents 
have recommended the use of pharmacologic thrombo-
prophylaxis in hospitalized patients with COVID-19 [2–4]. 
Most of these guidelines [2–4] recommend the use of unfrac-
tionated heparin (UFH) or low molecular weight heparin 
(LMWH), though the consensus is yet to reach in the rec-
ommendations of prophylactic, intermediate, or therapeu-
tic (full) dose anticoagulation. Nevertheless, it is not fully 
understood how effective pharmacologic thromboprophy-
laxis in preventing VTE among COVID-19 critically ill 
patients. We seek to systematically review the available evi-
dence to help guide clinicians weighing up decisions regard-
ing the anticoagulation approach for COVID-19 patients 
admitted to intensive care units.
Methods
This systematic review with meta-analysis was conducted 
with adherence to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-analyses (PRISMA) guidelines 
[5]. Two authors (CSK and SSH) independently performed a 
systematic literature search in PubMed, and Google Scholar 
and two preprint servers (medRxiv and SSRN) up to 25th 
June 2020. Search terms are depicted in Table S1. The titles 
and abstracts of the resulting articles were examined to 
exclude irrelevant studies. The full texts of the remaining 
articles were read to determine if these articles meet our 
eligibility criteria. Bibliographies of retrieved articles were 
also reviewed for additional studies. The studies eligible for 
inclusion reported on the prevalence of venous thromboem-
bolic event (deep vein thrombosis and pulmonary embolism) 
in patients admitted to the intensive care unit (ICU) receiv-
ing any type of anticoagulation (prophylactic or therapeutic). 
Articles were excluded if they consist of no original data, 
report combined arterial and venous thromboembolic events, 
report mixed ICU and medical patients, or report no phar-
macologic thromboprophylaxis. Case study, case series, and 
case report that may not reflect the true prevalence of VTE 
were also excluded.
Two authors (CSK and SSH) independently reviewed 
the primary studies to assess the appropriateness for 
inclusion and data were extracted. Any discrepancies were 
addressed by a joint re-evaluation of the original article. 
The information extracted from each study included the 
name of the first author, the country from which the study 
was reported, the design of the study, age information of 
patients, the proportion of patients with a reported previ-
ous history of VTE, information on body weight or body 
mass index, information on the anticoagulant regimen, 
and the proportion of patients who developed VTE.
The outcome measure was the prevalence of patients 
receiving anticoagulants who developed VTE from indi-
vidual studies. The pooled prevalence (and 95% confidence 
interval [CI]) of VTE among patients receiving anticoagu-
lant were calculated using the random-effects model. Sub-
group pooled analyses were performed with studies reported 
prophylactic anticoagulation alone and with studies reported 
mixed prophylactic and therapeutic anticoagulation. All 
meta-analytical calculations were performed using Meta XL, 
version 5.3 (EpiGear International, Queensland, Australia) 
[6]. We examined the heterogeneity between studies using 
the I2 statistics with 50% as the threshold for statistically 
significant heterogeneity.
Results
Our search yielded 1,056 titles from the selected databases 
(Fig. 1), of which 535 titles were duplicates. The remain-
ing 521 records were screened as per PRISMA guidelines 
against the eligibility criteria described in the previous sec-
tion. A total of 493 records were excluded after reading the 
title and abstract. The full-texts of the remaining 28 articles 
were retrieved for a detailed evaluation. Sixteen articles were 
excluded due to reasons including absence of original data, 
reported mixed intensive care units and medical patients, 
case study/series/report, reported combined arterial and 
venous thromboembolic events and reported no pharmaco-
logic thromboprophylaxis.
We eventually identified twelve studies [7–18] that 
reported the prevalence of VTE among ICU patients receiv-
ing prophylactic or therapeutic anticoagulation: three studies 
from France [7–9], two studies each from the Netherlands 
[10, 11], Italy [12, 13], the United Kingdom [14, 15], and 
one study each from the United States [16], China [17], and 
Germany [18]. The information extracted from each study 
is presented in Table 1. The number of patients admitted 
to intensive care units ranged widely from 20 to 184. Eight 
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out of eleven studies used a retrospective chart review as 
their study design [7, 9–16], whereas among the remaining 
three studies, two reported prospectively enrolled cohort [8, 
18] and one reported a cross-sectional analysis [17]. The 
mean/median age of patients ranged from 59 to 70 years 
old. Though not all studies reported on the proportion of 
patients with the previous history of VTE, we observed a 
low proportion (0-5.3%) in studies [7–10, 12, 14] which 
reported the figures except the study by Zerwes et al. [18] 
which reported a proportion of 10.0%. All studies [7–18] 
utilized LMWH or unfractionated heparin as their pharma-
cologic thromboprophylaxis approach, though with a mixed 
proportion of patients receiving either prophylactic doses or 
therapeutic doses.
The pooled prevalence of VTE among ICU patients 
receiving prophylactic or therapeutic anticoagulation across 
all studies was 31% (95% CI 20–43%; I2: 92%) (Fig. 2). 
Subgroup pooled analysis limited to studies reported pro-
phylactic anticoagulation alone in all patients included 
[14–17] reported a pooled prevalence of VTE of 38% (95% 
CI 10–70%; I2: 96%) (Supplementary Fig. S1). Subgroup 
pooled analysis limited to studies reported mixed therapeu-
tic and prophylactic anticoagulation in all patients included 
[7–13, 18] reported a pooled prevalence of VTE of 27% 
(95% CI 17–40%; I2: 89%) (Supplementary Fig. S2).
Discussion
The hypercoagulable state in COVID-19, which has been 
termed thrombo-inflammation or COVID-19-associated 
coagulopathy (CAC) by some experts, can be explained in 
terms of Virchow’s triad: endothelial injury, stasis of blood 
Fig. 1  Study selection process 
(PRISMA)
535 duplicate records excluded 
521 records screened
493 records excluded (not meeng the 
inclusion criteria)
16 full-text arcles excluded: 
4 consists of no original data;
4 reported mixed intensive care units and medical paents
4 case study/series/report;
2 reported combined arterial and venous thromboembolic events; 
2 reported no pharmacologic thromboprophylaxis
28 full-text arcles assessed for eligibility
1,056 records idenfied through database searching:
PUBMED (n=524), Google Scholar (n=405) & medRxiv 
(n=101), SSRN (n=26)
12 arcles included in quantave synthesis
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Table 1  Summary of studies reporting on the proportion of VTE among COVID-19 patients in ICU receiving anticoagulation
Study Country Study design Mean/
median 
age (y)
Proportion of 
patients with 
previous VTE 
(%)
Body weight/
BMI
Anticoagulant 
regimen
Proportion of 
patients who 
developed VTE 
(n/N)
Llitjos et al. [7] France Retrospective, 
multicenter
68 3.8 No mention LMWH or UFH
Prophylactic 
anticoagula-
tion: 31.0%
Therapeutic 
anticoagula-
tion: 69.0%
18/26; 69.2%
Helms et al. [8] France Prospective, 
multicentre
631 5.3 No mention LMWH or UFH
Prophylactic 
anticoagula-
tion: 70.0%
Therapeutic 
anticoagula-
tion: 30.0%
27/150; 18.0%
Fraissé et al. [9] France Retrospective, 
single-center
61 5.4 Median BMI: 
30 kg/m2
No mention of 
anticoagulant
Prophylactic 
anticoagula-
tion: 46.7%
Therapeutic 
anticoagula-
tion: 53.3%
19/92; 20.6%
Middledorp et al. 
[10]
Netherlands Retrospective, 
single-center
62 2.8 Median BMI: 
27 kg/m2; 17% 
of patients 
with body 
weight ≥ 100 kg
LMWH
Both prophylac-
tic and thera-
peutic antico-
agulationwere 
utilized though 
no breakdown 
on prophylactic 
vs. therapeutic 
anticoagulation 
was provided
35/75; 46.7%
Klok et al. [11] Netherlands Retrospective, 
multicenter
64 No mention Mean body 
weight: 87 kg
LMWH
Prophylactic 
anticoagula-
tion: 90.8%
Therapeutic 
anticoagula-
tion: 9.2%
28/184; 15.2%
Lodigiani et al. 
[12]
Italy Retrospective, 
single-center
61 0 22.9% of 
patients with 
BMI ≥ 30 kg/m2
LMWH
Prophylactic 
anticoagula-
tion: 95.8%
Therapeutic 
anticoagula-
tion: 4.2%
8/48; 16.7%
Spiezia et al. 
[13]
Italy Retrospective, 
single-center
67 No mention Mean BMI: 30 kg/
m2
LMWH
No breakdown 
on prophylactic 
vs. therapeutic 
anticoagulation 
was provided
5/22; 22.7%
Thomas et al. 
[14]
United Kingdom Retrospective, 
single-center
59 1.6 80.9% of patients 
with body 
weight between 
50–99 kg
LMWH
Prophylactic 
anticoagula-
tion: 100.0%
17/62; 27.4%
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BMI body mass index, LMWH Low molecular weight heparin, UFH unfractionated heparin, VTE venous thromboembolism
Table 1  (continued)
Study Country Study design Mean/
median 
age (y)
Proportion of 
patients with 
previous VTE 
(%)
Body weight/
BMI
Anticoagulant 
regimen
Proportion of 
patients who 
developed VTE 
(n/N)
Desborough 
et al. [15]
United Kingdom Retrospective, 
single-center
59 No mention Median BMI: 
28 kg/m2
LMWH
Prophylactic 
anticoagula-
tion: 100.0%
10/66; 15.2%
Maatman et al. 
[16]
United States Retrospective, 
multicenter
61 No mention Mean BMI: 
34.8 kg/m2
LMWH or UFH
Prophylactic 
anticoagula-
tion: 100.0%
29/107; 27.1%
Ren et al. [17] China Cross-sectional, 
multicentre
70 No mention 33.3% of 
patients with 
BMI ≥ 24 kg/m2
LMWH
Prophylactic 
anticoagula-
tion: 100.0%
41/47; 87.2%
Zerwes et al. 
[18]
Germany Prospective, 
single-centre
64 10.0 Mean BMI: 
28.1 kg/m2
LMWH or UFH
Both prophylac-
tic and thera-
peutic antico-
agulationwere 
utilized though 
no breakdown 
on prophylactic 
vs. therapeutic 
anticoagulation 
was provided
4/20; 20.0%
Fig. 2  Pooled VTE prevalence 
(%) in COVID-19 patients 
admitted to ICU receiving 
anticoagulation
Prevalence
2.0 4.0 6.0 8.0 1
Study 
Desborough et al, UK  
Klok et al, Netherlands  
Lodigiani et al, Italy  
Helms et al, France  
Zerwes et al, Germany  
Fraissé et al, France  
Spiezia et al, Italy  
Maatman et al, US  
Thomas et al, UK  
Overall 
Q=143.80, p=0.00, I2=92%
Middledo et al, Netherlands  
Llitjos et al, France  
Ren et al, China  
    Prev (95% CI)          % Weight
   0.15  (  0.07,  0.25)      8.5
   0.15  (  0.10,  0.21)      9.0
   0.17  (  0.07,  0.29)      8.3
   0.18  (  0.12,  0.25)      9.0
   0.20  (  0.05,  0.41)      7.2
   0.21  (  0.13,  0.30)      8.8
   0.23  (  0.07,  0.43)      7.4
   0.27  (  0.19,  0.36)      8.8
   0.27  (  0.17,  0.39)      8.5
   0.31  (  0.20,  0.43)    100.0
   0.47  (  0.35,  0.58)      8.6
   0.69  (  0.50,  0.86)      7.6
   0.87  (  0.76,  0.95)      8.3
 S. S. Hasan et al.
1 3
flow, and hypercoagulability. In terms of endothelial injury, 
there is evidence of direct invasion of endothelial cells by the 
SARS-CoV-2 virus, potentially leading to cell injury [19]. 
Other sources of endothelial injury may include intravascu-
lar catheters and mediators of the acute systemic inflamma-
tory response such as cytokines (e.g., interleukin-6) other 
acute phase reactants [20]. On the other hand, immobili-
zation during hospitalization with COVID-19, especially 
severely ill patients admitted to intensive care units, can 
cause stasis of blood flow. In terms of hypercoagulability, 
many changes in circulating prothrombotic factors have 
been reported or proposed in patients with severe COVID-
19, including elevated factor VIII level, elevated fibrinogen 
level, circulating prothrombotic microparticles, and neutro-
phil extracellular traps [21–23].
Therefore, with the recognition of hypercoagulability 
in COVID-19, the need for effective thromboprophylaxis 
cannot be overstated. Since no head-to-head trial compar-
ing pharmacologic thromboprophylaxis versus no pharma-
cologic thromboprophylaxis among ICU patients, as of the 
time of writing (doubt such trial will be conducted), a com-
parison of our findings (Table 1) with non-COVID-19 criti-
cal care patients is worth exploring. The landmark PROphy-
laxis for ThromboEmbolism in Critical care (PROTECT) 
trial that compared the comparative effectiveness of LMWH 
and UFH in 3764 critically ill patients found the average 
incidence of VTE of 8.2% and 9.9%, respectively [24]. A 
subsequent analysis of the PROTECT study by Lim et al. 
found an overall incidence of VTE of 7.7% [25]. A more rel-
evant comparison of our findings is with critically ill patients 
who developed sepsis during their hospitalisation, and thus 
may be at a higher risk of VTE prophylaxis failure. The 
incidence of VTE in sepsis patients admitted to ICU ranged 
from 12.5% in a retrospective study of 335 patients to 37% 
in a prospective study of 113 patients [26, 27]. it is important 
to note that in the aforementioned prospective study, the 
average body mass index (BMI) of included patients was 
31.7 kg/m2 and high BMI is a known factor of VTE as noted 
in the PROTECT sub-analysis [25].
Since preliminary evidence indicating a possibility of a 
higher rate of pharmacologic thromboprophylaxis failure 
in ICU patients with COVID-19 compared to their non-
COVID-19 counterparts, a reconsideration of the current 
approach may be needed, including the need to implement 
individualized VTE prophylaxis. It has previously been dem-
onstrated that prophylactic LMWH dosing is associated with 
subtherapeutic anti-factor Xa levels in critically ill patients, 
and therefore an individualized dosing approach based on 
anti-factor Xa monitoring may be useful in COVID-19 
patients [28–31]. Indeed, it has also been recently discovered 
that prophylactic LMWH dosing was associated with sub-
therapeutic anti-factor Xa levels among COVID-19 patients 
admitted to intensive care units. Dutt et al. [32] reported that 
95% of COVID-19 patients had sub-therapeutic anti-factor 
Xa levels despite prophylactic LMWH, a figure which was 
about 3.5 times higher compared to the patients admitted to 
medical wards (27%).
The outcomes of individual adjustment of LMWH dos-
ing guided by anti-factor Xa monitoring are encouraging, 
though thus far it was only investigated in surgical or trauma 
patients [33, 34]. The lower pooled prevalence of VTE in 
studies reported mixed anticoagulation approach (prophylac-
tic and therapeutic) compared to studies reported prophylac-
tic anticoagulation only (27% versus 38%) may have been 
possibly driven by on average higher rate of attaintment of 
target anti-factor Xa levels due to the use of therapeutic anti-
coagulation in some included patients. Nevertheless, sub-
therapeutic anti-factor Xa levels have also been observed 
in COVID-19 patients on twice-daily therapeutic LMWH 
regimens [35].
Similarly, anti-factor Xa monitoring in patients receiv-
ing unfractionated heparin is associated with better attain-
ment of therapeutic anticoagulation compared to activated 
partial thromboplastin time monitoring whereby it shortens 
the time to reach the therapeutic range as well as improves 
the length of time in the therapeutic range [36]. In fact, the 
phenomenon of heparin resistance has been observed up 
to 80% of COVID-19 patients treated with unfractionated 
heparin in which there was a need for high doses of unfrac-
tionated heparin (more than 35,000 IU/day) to achieve the 
target activated partial thromboplastin time presumably 
due to increased factor VIII levels [37]. Patients requiring 
high doses of unfractionated heparin to achieve the target 
activated partial thromboplastin time may also develop life-
threatening bleeding events if they proceed without monitor-
ing of antithrombotic activity via an anti-factor Xa assay.
There has been an increased interest to utilize throm-
boelastography (TEG) or rotational thromboelastometry 
(ROTEM) in critically ill COVID-19 patients where both 
tests may be useful to inform individualized clinical deci-
sion-making regarding VTE prophylaxis among COVID-19 
patients [38]. Viscoelastic observations with TEG among 
critically ill COVID-19 patients in the intensive care unit 
revealed hypercoagulable state with decreased R time and 
K time as well as elevated fibrinogen activity greater than a 
73° angle and maximum amplitude more than 65 mm with 
heparinase correction [39, 40]. Whereas, viscoelastic obser-
vations with ROTEM observed significantly higher maxi-
mum clot firmness and clotting time as well as significantly 
shorter clot formation time among COVID-19 patients com-
pared with healthy controls (p < 0.001) [41]. In fact, com-
parison among COVID-19 patients reported that maximum 
clot firmness and clotting time were significantly longer in 
those admitted to medical wards relative to those in special-
ized wards (intermediate wards/intensive care units). Thus 
far, there is only one randomized controlled trial [42] which 
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assessed TEG-based protocol for the dosing of unfraction-
ated heparin among patients receiving extracorporeal mem-
brane oxygenation which reported reduced dose of heparin 
used compared with aPTT-based protocol, with no differ-
ence between the two protocols in terms of thrombotic and 
haemorrhagic events.
Our analysis does have some limitations. Firstly, there 
were no randomized controlled trials available that inves-
tigate the effectiveness of heparin-based pharmacological 
thromboprophylaxis among critically ill COVID-19 patients 
at the time of the literature search. Secondly, ten out of 
twelve studies included in our meta-analysis originate from 
European countries, which may limit the generalizability 
of the results to COVID-19 populations from other conti-
nents. Thirdly, we were unable to perform subgroup analy-
sis strictly on patients receiving therapeutic anticoagulation 
and patients receiving prophylactic anticoagulation since the 
included original studies did not segregate their data based 
on the intensity of anticoagulation.
Conclusions
Further study into anticoagulant selection, dosing regimens, 
and monitoring are needed in this important population of 
critically ill COVID-19 patients admitted to intensive care 
units. Until prospective or randomised studies with a clear 
description of baseline factors and adequate follow up, the 
best approach for managing VTE will be uncertain. Individ-
ualised rather than protocolised thromboprophylaxis would 
appear prudent at interim. Besides, maintaining a strong 
index of suspicion for VTE and the possibility of chemo-
prophylaxis failure is recommended. Likewise, future studies 
may investigate the effectiveness of anti-factor Xa-guided 
or TEG/ROTEM-based heparin dosing in reducing the high 
prevalence of thromboprophylaxis failure in COVID-19 
patients.
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